- Home
- PRME vs VSTM Comparison
PRME vs VSTM Comparison
Compare PRME & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- VSTM
- Stock Information
- Founded
- PRME 2019
- VSTM 2010
- Country
- PRME United States
- VSTM United States
- Employees
- PRME N/A
- VSTM N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- VSTM Health Care
- Exchange
- PRME Nasdaq
- VSTM Nasdaq
- Market Cap
- PRME 693.5M
- VSTM 598.2M
- IPO Year
- PRME 2022
- VSTM 2012
- Fundamental
- Price
- PRME $4.67
- VSTM $9.13
- Analyst Decision
- PRME Buy
- VSTM Strong Buy
- Analyst Count
- PRME 6
- VSTM 9
- Target Price
- PRME $8.88
- VSTM $13.38
- AVG Volume (30 Days)
- PRME 2.9M
- VSTM 2.6M
- Earning Date
- PRME 11-11-2025
- VSTM 11-05-2025
- Dividend Yield
- PRME N/A
- VSTM N/A
- EPS Growth
- PRME N/A
- VSTM N/A
- EPS
- PRME N/A
- VSTM N/A
- Revenue
- PRME $4,961,000.00
- VSTM $2,137,000.00
- Revenue This Year
- PRME $179.58
- VSTM $88.50
- Revenue Next Year
- PRME N/A
- VSTM $398.66
- P/E Ratio
- PRME N/A
- VSTM N/A
- Revenue Growth
- PRME 739.42
- VSTM N/A
- 52 Week Low
- PRME $1.11
- VSTM $2.54
- 52 Week High
- PRME $5.17
- VSTM $11.25
- Technical
- Relative Strength Index (RSI)
- PRME 67.60
- VSTM 53.24
- Support Level
- PRME $3.09
- VSTM $9.25
- Resistance Level
- PRME $4.18
- VSTM $10.04
- Average True Range (ATR)
- PRME 0.31
- VSTM 0.69
- MACD
- PRME 0.11
- VSTM -0.16
- Stochastic Oscillator
- PRME 98.14
- VSTM 12.03
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.